Valeant Pharmaceuticals International, Inc. (VRX) plummeted -1.2 percent and ended the day at $10.68. The Average Volume of the company is 18.51 Million and P/E (price to earnings) ratio is 0, while Forward P/E ratio is 2.26.
Morgan Stanley Downgrade its coverage for Valeant Pharmaceuticals International, Inc. (VRX) in a note sent to investors on 15-Dec-16. The research firm Downgrade the stock to Equal-Weight. Moreover, Mizuho issued Downgrade rating for the stock on 23-Nov-16. Rodman & Renshaw also Downgrade the company to Neutral on 10-Nov-16, 2016. Additionally, Morgan Stanley Upgrade its ratings on the stock to Overweight.
The highest price VRX stock touched in the last 12 month was $38.5 and the lowest price it hit in the same period was $10.35. The stock has a Return on Assets of -5.2 percent, Return on Investment of -1.6 percent and a Return on Equity of -52.7 percent. The company’s market cap is $3.71 Billion.
Now we look at the Moving Averages, the 200-day is -45.9, the 50-day is -21.98 and the 20-day is -9.23. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also help in determining where it may be possibly heading.
Looking forward, the company is expected to report earnings of $0.9 per share for the current quarter. Revenue is expected in between 333 Million and 270.8 Million with an average of 297.08 Million.
When we look at the recommendation trends, the stock presently has an average brokerage recommendation of 4. Out of 20 brokerage recommendations, 3 gave a Strong Buy, 0 issued a Buy, 13 issued Hold, 3 rated Under-perform and 1 issued a Sell.
Valeant Pharmaceuticals International, Inc. (VRX) performance during the last one year Degraded -63.15 percent, while its year to date (YTD) performance showed a Negative trend of -26.45 percent. The stock Fell -58.75 percent over the past six months. The stock’s quarterly performance indicates a Negative momentum of -25.57 percent, whereas its last one month trend is Pessimistic with -36.09 percent. Its weekly performance showed a downward trend of -0.37 percent.
Profitability analysis helps a great deal in making investment decision. Net profit margin of the company was recorded at -24.9 percent, operating profit margin was -5.9 percent, whereas gross profit margin stands at 73 percent. Beta factor was calculated at -0.14.
Valeant Pharmaceuticals International, Inc. (VRX) has 345.47 Million shares outstanding and 332.18 Million shares were floated in market. The short ratio in the company’s stock is documented at 2.54 and the short float is around of 14.16%. The stock’s average true range of stands at 0.63, while the relative strength index is 34.02.
Liquidity ratios helps investors to determine a company’s ability to pay off its debts. For the most recent quarter, quick ratio was 1.1, current ratio was 1.4, LT Debt/Equity ratio was 9.47 and Total Debt/Equity ratio was 9.47.